Results 221 to 230 of about 65,558 (345)

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Recombinant expression of receptor binding domains of all eight subtypes of botulinum neurotoxin type A for generation of antitoxins with broad reactivity. [PDF]

F1000Res
Quynh Pham N, Mai TT, Dang TBA, Huong Tran L, Mai Vu Q, Trong Nguyen C, Thi Phuong Tran A, Dang TNM, Tran VA, Huy Tran T, Tran VK, Quang Le H.   +11 more
europepmc   +1 more source

Exploring biomarkers of neurodegeneration in epilepsy: Critical insights

Epileptic Disorders, EarlyView.
Abstract The advent of biofluid biomarkers for neurodegenerative disorders has precipitated a surge in recent evidence regarding their role in epilepsy. In this literature review, we examine the diagnostic, prognostic, and therapeutic potential of several biomarkers, including amyloid‐beta (Aβ) protein, total (t‐tau), phosphorylated tau (p‐tau) protein,
Rida Farhan, Syeda Amrah Hashmi, Jaideep Kapur, Anelyssa D'Abreu, Vineet Punia, Carol Manning, Vanessa L. Smith, Ifrah Zawar   +7 more
wiley   +1 more source

The 1.3-Å Structure of a Scorpion Neurotoxin

, 1982
F. L. Suddath, Charles E. Bugg, Steven A. Ealick, Robert J. Almassy, Juan C. Fontecilla‐Camps   +4 more
openalex   +1 more source

Sensorineural hearing loss from quinolinic acid: A neurotoxin in middle ear effusions [PDF]

, 1994
Robert F. Yellon, Elizabeth Kirk Rose, Margaret A. Kenna, William J. Doyle, Margaretha L. Casselbrant, Warren F. Diven, Theresa L. Whiteside, J. Douglas Swarts, Melvyn P. Heyes   +8 more
openalex   +1 more source

The hitochemical changes of non-dopaminergic neurons of the mouse striatum induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), a nigrostriatal dopaminergic neurotoxin used for a model of Parkinson's disease

, 1986
Toshikazu Hochi
openalex   +2 more sources

Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence [PDF]

, 1992
Sarah M. Whelan, Michael J. Elmore, Nicola J. Bodsworth, John K. Brehm, Tony Atkinson, Nigel P. Minton   +5 more
openalex   +1 more source

Compound heterozygosity of a De novo 16q24.1 deletion and missense mutation in COX4I1 leads to developmental regression, intellectual disability, and seizures

Epilepsia Open, EarlyView.
Abstract The COX4I1 is responsible for encoding a crucial component of cytochrome c oxidase, integral to electron transport in the mitochondrial respiratory chain. Mutations in COX4I1 can result in a rare autosomal recessive disorder characterized by growth retardation, slow weight gain, microcephaly, and potentially, hematologic symptoms such as ...
Zhen Liu, Mei He, Xuan Luo, Hu Pan, Xiao Mao, Jinping Su   +5 more
wiley   +1 more source

A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly.

, 1993
Anton de Paiva, Bernard Poulain, Gary W. Lawrence, Clifford C. Shone, L Tauc, J. Oliver Dolly   +5 more
openalex   +1 more source

Inherited metabolic epilepsies–established diseases, new approaches

Epilepsia Open, EarlyView.
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley   +1 more source